NCT01781637View on ClinicalTrials.gov

Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

May 31, 2022

Conditions
Peanut AllergyFood Allergy
Interventions
DRUG

Omalizumab

subcutaneous injection

DRUG

placebo

subcutaneous injection

Trial Locations (4)

19104

Children's Hospital of Philadelphia, Philadelphia

60611

Lurie Children's Hospital, Chicago

94305

Stanford University, Stanford

02115

Division of Immunology, Children's Hospital Boston, Boston

All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Stanford University

OTHER

collaborator

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER

lead

Boston Children's Hospital

OTHER

NCT01781637 - Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial | Biotech Hunter | Biotech Hunter